Cargando…

E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements

Loss of E-cadherin expression due to mutation of the CDH1 gene is a characteristic feature of invasive lobular breast cancer (ILBC). Beta-catenin, which binds to the cytoplasmic domain of E-cadherin, is simultaneously downregulated, reflecting disassembly of adherens junctions (AJs) and loss of cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Christgen, Matthias, Bartels, Stephan, van Luttikhuizen, Jana L., Bublitz, Janin, Rieger, Luisa U., Christgen, Henriette, Stark, Helge, Sander, Bjoern, Lehmann, Ulrich, Steinemann, Doris, Derksen, Patrick W. B., Kreipe, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685979/
https://www.ncbi.nlm.nih.gov/pubmed/32572153
http://dx.doi.org/10.1038/s41379-020-0591-3
_version_ 1783613273379176448
author Christgen, Matthias
Bartels, Stephan
van Luttikhuizen, Jana L.
Bublitz, Janin
Rieger, Luisa U.
Christgen, Henriette
Stark, Helge
Sander, Bjoern
Lehmann, Ulrich
Steinemann, Doris
Derksen, Patrick W. B.
Kreipe, Hans
author_facet Christgen, Matthias
Bartels, Stephan
van Luttikhuizen, Jana L.
Bublitz, Janin
Rieger, Luisa U.
Christgen, Henriette
Stark, Helge
Sander, Bjoern
Lehmann, Ulrich
Steinemann, Doris
Derksen, Patrick W. B.
Kreipe, Hans
author_sort Christgen, Matthias
collection PubMed
description Loss of E-cadherin expression due to mutation of the CDH1 gene is a characteristic feature of invasive lobular breast cancer (ILBC). Beta-catenin, which binds to the cytoplasmic domain of E-cadherin, is simultaneously downregulated, reflecting disassembly of adherens junctions (AJs) and loss of cell adhesion. E-cadherin to P-cadherin expression switching can rescue AJs and cell adhesion. However, P-cadherin has not been implicated in ILBC, so far. We aimed to characterize 13 ILBCs with exceptional histomorphology, which we termed ILBCs with tubular elements. The CDH1 mutational status was determined by next generation sequencing and whole-genome copy number (CN) profiling. Expression of cadherins was assessed by immunohistochemistry. ILBCs with tubular elements were ER-positive (13/13) and HER2-negative (13/13) and harbored deleterious CDH1 mutations (11/13) accompanied by loss of heterozygosity due to deletion of chromosome 16q22.1 (9/11). E-cadherin expression was lost or reduced in noncohesive tumor cells and in admixed tubular elements (13/13). Beta-catenin expression was lost in noncohesive tumor cells, but was retained in tubular elements (11/13), indicating focal rescue of AJ formation. N-cadherin and R-cadherin were always negative (0/13). Strikingly, P-cadherin was commonly positive (12/13) and immunoreactivity was accentuated in tubular elements. Adjacent lobular carcinoma in situ (LCIS) was always P-cadherin-negative (0/7). In a reference cohort of LCIS specimens, P-cadherin was constantly not expressed (0/25). In a reference cohort of invasive mammary carcinomas, P-cadherin-positive cases (36/268, 13%) were associated with triple-negative nonlobular breast cancer (P < 0.001). Compared with ILBCs from the reference cohort, P-cadherin expression was more common in ILBCs with tubular elements (12/13 versus 7/84, P < 0.001). In summary, E-cadherin to P-cadherin switching occurs in a subset of ILBCs. P-cadherin is the molecular determinant of a mixed-appearing histomorphology in ILBCs with tubular elements.
format Online
Article
Text
id pubmed-7685979
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-76859792020-12-03 E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements Christgen, Matthias Bartels, Stephan van Luttikhuizen, Jana L. Bublitz, Janin Rieger, Luisa U. Christgen, Henriette Stark, Helge Sander, Bjoern Lehmann, Ulrich Steinemann, Doris Derksen, Patrick W. B. Kreipe, Hans Mod Pathol Article Loss of E-cadherin expression due to mutation of the CDH1 gene is a characteristic feature of invasive lobular breast cancer (ILBC). Beta-catenin, which binds to the cytoplasmic domain of E-cadherin, is simultaneously downregulated, reflecting disassembly of adherens junctions (AJs) and loss of cell adhesion. E-cadherin to P-cadherin expression switching can rescue AJs and cell adhesion. However, P-cadherin has not been implicated in ILBC, so far. We aimed to characterize 13 ILBCs with exceptional histomorphology, which we termed ILBCs with tubular elements. The CDH1 mutational status was determined by next generation sequencing and whole-genome copy number (CN) profiling. Expression of cadherins was assessed by immunohistochemistry. ILBCs with tubular elements were ER-positive (13/13) and HER2-negative (13/13) and harbored deleterious CDH1 mutations (11/13) accompanied by loss of heterozygosity due to deletion of chromosome 16q22.1 (9/11). E-cadherin expression was lost or reduced in noncohesive tumor cells and in admixed tubular elements (13/13). Beta-catenin expression was lost in noncohesive tumor cells, but was retained in tubular elements (11/13), indicating focal rescue of AJ formation. N-cadherin and R-cadherin were always negative (0/13). Strikingly, P-cadherin was commonly positive (12/13) and immunoreactivity was accentuated in tubular elements. Adjacent lobular carcinoma in situ (LCIS) was always P-cadherin-negative (0/7). In a reference cohort of LCIS specimens, P-cadherin was constantly not expressed (0/25). In a reference cohort of invasive mammary carcinomas, P-cadherin-positive cases (36/268, 13%) were associated with triple-negative nonlobular breast cancer (P < 0.001). Compared with ILBCs from the reference cohort, P-cadherin expression was more common in ILBCs with tubular elements (12/13 versus 7/84, P < 0.001). In summary, E-cadherin to P-cadherin switching occurs in a subset of ILBCs. P-cadherin is the molecular determinant of a mixed-appearing histomorphology in ILBCs with tubular elements. Nature Publishing Group US 2020-06-22 2020 /pmc/articles/PMC7685979/ /pubmed/32572153 http://dx.doi.org/10.1038/s41379-020-0591-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Christgen, Matthias
Bartels, Stephan
van Luttikhuizen, Jana L.
Bublitz, Janin
Rieger, Luisa U.
Christgen, Henriette
Stark, Helge
Sander, Bjoern
Lehmann, Ulrich
Steinemann, Doris
Derksen, Patrick W. B.
Kreipe, Hans
E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
title E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
title_full E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
title_fullStr E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
title_full_unstemmed E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
title_short E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
title_sort e-cadherin to p-cadherin switching in lobular breast cancer with tubular elements
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685979/
https://www.ncbi.nlm.nih.gov/pubmed/32572153
http://dx.doi.org/10.1038/s41379-020-0591-3
work_keys_str_mv AT christgenmatthias ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT bartelsstephan ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT vanluttikhuizenjanal ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT bublitzjanin ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT riegerluisau ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT christgenhenriette ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT starkhelge ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT sanderbjoern ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT lehmannulrich ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT steinemanndoris ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT derksenpatrickwb ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements
AT kreipehans ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements